Similarly, AZD8055, a selective mTORC1 and mTORC2 inhibitor, reduced MCL1 expression and induced tumor regression in vivo in different T-ALL disease models [38]. This evidence concerns the gene MCL1 and acute lymphoblastic leukemia.